Iradimed Corp IRMD
We take great care to ensure that the data presented and summarized in this overview for IRADIMED CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IRMD
View all-
Nine Ten Capital Management LLC Evanston, IL872KShares$63.7 Million15.71% of portfolio
-
Black Rock Inc. New York, NY818KShares$59.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA561KShares$41 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny492KShares$35.9 Million0.04% of portfolio
-
Copeland Capital Management, LLC458KShares$33.4 Million0.58% of portfolio
-
Geode Capital Management, LLC Boston, MA261KShares$19.1 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX215KShares$15.7 Million0.0% of portfolio
-
Ranger Investment Management, L.P. Dallas, TX200KShares$14.6 Million0.77% of portfolio
-
State Street Corp Boston, MA177KShares$12.9 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA154KShares$11.3 Million0.02% of portfolio
Latest Institutional Activity in IRMD
Top Purchases
Top Sells
About IRMD
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Insider Transactions at IRMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 06
2025
|
Monty K Allen |
SELL
Open market or private sale
|
Direct |
1,102
-5.25%
|
$76,038
$69.1 P/Share
|
|
Jun 20
2025
|
John Glenn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,412
-9.7%
|
$81,896
$58.24 P/Share
|
|
Jun 20
2025
|
John Glenn CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,796
+28.47%
|
-
|
|
Dec 07
2024
|
Monty K Allen |
BUY
Exercise of conversion of derivative security
|
Direct |
2,947
+6.76%
|
-
|
|
Dec 07
2024
|
Anthony Vuoto |
BUY
Exercise of conversion of derivative security
|
Direct |
2,947
+8.19%
|
-
|
|
Dec 07
2024
|
Hilda Frederique Scharen Guivel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,196
+20.19%
|
-
|
|
Dec 07
2024
|
James B Hawkins |
BUY
Exercise of conversion of derivative security
|
Direct |
2,947
+3.42%
|
-
|
|
Dec 02
2024
|
John Glenn CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-36.32%
|
$135,000
$54.18 P/Share
|
|
Nov 06
2024
|
Anthony Vuoto |
SELL
Open market or private sale
|
Direct |
2,690
-15.89%
|
$147,950
$55.99 P/Share
|
|
Oct 14
2024
|
Hilda Frederique Scharen Guivel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,767
+33.34%
|
-
|
|
Jun 20
2024
|
John Glenn CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,412
-13.87%
|
$59,304
$42.53 P/Share
|
|
Jun 20
2024
|
John Glenn CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,796
+36.28%
|
-
|
|
Jun 03
2024
|
Monty K Allen |
SELL
Open market or private sale
|
Direct |
1,947
-9.74%
|
$83,721
$43.37 P/Share
|
|
Dec 27
2023
|
Roger E. Susi CEO, PRESIDENT, CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
5,000
-2.98%
|
$230,000
$46.51 P/Share
|
|
Dec 26
2023
|
Roger E. Susi CEO, PRESIDENT, CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
5,000
-2.89%
|
$230,000
$46.0 P/Share
|
|
Dec 21
2023
|
Roger E. Susi CEO, PRESIDENT, CHAIRMAN |
SELL
Bona fide gift
|
Indirect |
300,000
-12.7%
|
-
|
|
Dec 19
2023
|
Roger E. Susi CEO, PRESIDENT, CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
5,000
-2.81%
|
$225,000
$45.14 P/Share
|
|
Dec 18
2023
|
Roger E. Susi CEO, PRESIDENT, CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
5,000
-2.73%
|
$220,000
$44.08 P/Share
|
|
Dec 14
2023
|
James B Hawkins |
SELL
Open market or private sale
|
Direct |
4,277
-9.8%
|
$188,188
$44.58 P/Share
|
|
Dec 14
2023
|
James B Hawkins |
BUY
Grant, award, or other acquisition
|
Direct |
4,277
+8.93%
|
$38,493
$9.84 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 17.6K shares |
|---|
| Open market or private sale | 6.29K shares |
|---|---|
| Payment of exercise price or tax liability | 1.41K shares |